Farther Finance Advisors, LLC
Position in BCRX — Biocryst Pharmaceuticals Inc
CIK 1992825
SAN FRANCISCO, CA
Position in BCRX
as of Jun 30, 2026
· filed Jul 17, 2026
Position Value
$65,510
+$11,342 QoQ
Shares Held
6,551
+15.1% QoQ
Ownership
0.003%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#257
of 316 holders
Holding Since
Mar 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in BCRX Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026Farther Finance Advisors, LLC holds $5,620,756 across 55 Drug Manufacturers - Specialty & Generic names. BCRX ranks #14 (1.2% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | UTHR |
UNITED THERAPEUTICS Corp
|
1,312 | $710,880 | |
| 2 | HIMS |
Hims & Hers Health, Inc.
|
20,420 | $707,961 | |
| 3 | ZTS |
Zoetis Inc.
|
8,686 | $624,175 | |
| 4 | VTRS |
Viatris Inc
|
39,209 | $622,638 | |
| 5 | TEVA |
Teva Pharmaceutical Industries Ltd
|
14,418 | $488,481 | |
| 6 | COLL |
Collegium Pharmaceutical, Inc
|
13,324 | $482,328 | |
| 7 | NBIX |
Neurocrine Biosciences Inc
|
2,503 | $421,855 | |
| 8 | TAK |
Takeda Pharmaceutical Co Ltd
|
21,332 | $341,951 |
All Filings in BCRX
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $65,510 | 6,551 | Shares | Sole | 2026-07-17 | |
| 2026-03-31 | $54,168 | 5,690 | Shares | Sole | 2026-04-07 | |
| 2025-12-31 | $89,637 | 11,492 | Shares | Sole | 2026-01-23 | |
| 2025-09-30 | $80,378 | 10,590 | Shares | Sole | 2025-10-14 | |
| 2025-06-30 | $22,229 | 2,481 | Shares | Sole | 2025-07-11 | |
| 2025-03-31 | $18,465 | 2,462 | Shares | Sole | 2025-04-14 | |
| 2024-03-31 | $304 | 60 | Shares | Sole | 2024-05-14 | |
| No filing history on record for this holder in this stock. | ||||||